September 30, 2024 02:14 PM EDT
Pharma
FDA+
Law

J&J pulls the plug on 340B re­bate mod­el changes op­posed by gov­ern­ment

Nicole DeFeudis

Editor

John­son & John­son has called off plans to im­ple­ment a new re­bate mod­el for 340B drug price dis­counts fol­low­ing threats from the fed­er­al gov­ern­ment. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Cal­i­for­ni­a's Gavin New­som ve­toes bi­par­ti­san PBM re­form bill

Po­sei­da shares in­cre­men­tal Phase 1 up­date for Roche-part­nered off-the-shelf CAR-T

Up­dat­ed: Roche buys Re­gor’s CDK in­hibitors for $850M up­front amid push to de­vel­op 20 ‘trans­for­ma­tive’ med­i­cines

Up­dat­ed: Prime Med­i­cine whit­tles down pipeline, signs gene edit­ing deal with Bris­tol My­ers

Kezar halts mid-stage lu­pus study af­ter four deaths

sponsored

3 Tiers for AAV Po­ten­cy As­say De­vel­op­ment Suc­cess

A service from the Financial Times